



Patient Consent for OncoScreen/Multi-Gene Cancer Panels

*Please initia	l next to each statement as acknowledgment that you have read and understand the information.
I unders	stand the following information regarding the test purpose and methodology:
	purpose of this molecular genetic test is to determine if you carry any mutation(s) causing increased risk to develop err. This test will include analysis of all genes included on the cancer panel indicated above.
The tresting	blood, body fluid, or tissue specimen submitted is required for isolation and purification of DNA for molecular genetic ng.
I underst	tand the following information regarding the results disclosure policy:
throug	to the complexity of DNA-based testing and the important implications of the test results, these results will be reported up the properties of the second physician (s) or genetic counselor and you should contact your provider to obtain the results of the Additionally, the test results could be released to all who, by law, may have access to such data.
I underst	tand the following information regarding test results:
Gene	es included on this test may be associated with several different types of cancer and are also associated with varying

Genes included on this test may be associated with several different types of cancer and are also associated with varying levels of cancer risk. Your healthcare provider's recommendations foryourmedical management could differ depending upon the test findings. All genes on this panel have been implicated in cancer predisposition and are associated with increased lifetime cancer risk(s), although these risks may differ, depending on the particular gene. For many of the genes, specific screening and medical management recommendations are available for individuals with mutations.

These genes include but are not limited to: APC, BMPR1, ABRCAI, BRCA2, CDH1, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, and TP53. Identification of a mutation in other genes can also impact medical management decisions and more data and specific recommendations are expected to emerge over time. Identification of a mutation in any gene does not imply that cancer screening and risk management options will be covered by health insurance. If mutations are identified in more than one gene on this panel, there may not be sufficient information available to determine your precise cancer risk. Therefore, the results of this genetic test may or may not have implications for your medical management and options including preventive screening/intervention or therapeutics based on your genetic testing result may change over time. Genetic test results have implications for your family members. If you are found to carry a mutation/variant in any of the genes analyzed, this may also have implications for your family members. This should be discussed with your healthcare provider. There are several types of genetic test results, including:

Positive- A mutation was identified in a gene(s) associated with increased cancer susceptibility. This means that you are at increased risk of developing cancer. The specific type(s) of cancer depend on the particular gene(s). Your healthcare provider will make cancer screening and medical management recommendations based on what is known about the gene(s) in which a mutation was found.

Negative- No mutations were identified inany of the genes tested. This result greatly reduces the likelihood that you have a mutation in the genes tested (see limitations of testing). Your healthcare provider willmake cancer screening and medical management recommendations based on your personal and/or family history.

Variant-Analteration was identified in one or more genes; however, there is not enough information to determine whether this change is associated with an increased risk for cancer. A thorough review of the variant and the associated literature may suggest that a variant is more likely to be disease-causing or benign. However, in some cases the significance remains unclear. Your healthcare provider will make cancer screening and medical management recommendations based on your personal and/or family history.

In addition to increasing cancer risk, some genes on this panel have also been implicated inother genetic conditions, which are inherited in a recessive manner. This means that if you are identified to carry a mutation in one of these genes and your child's other biological parent also carries a mutation in the same gene there is a 25% chance of a child being affected by one of these recessive conditions. The overall risk of havinga child affected with one of these conditions is low. Further testing of you or your reproductive partner may be recommended based on the results ofthis rest.

Pre- and post-test genetic counseling provided by a qualified specialist, such as a genetic counselor or medical geneticist, is a recommended option for all individuals undergoing genetic testing.

I understand that this molecular genetic test may require an additional blood, body fluid, or tissue sample to obtain accurate results.



Patient Name (Print)

Dr. Althea McPhail, Lab Director / CLIA #11D2108137 1180 Beaver Ruin Rd., STE B, Norcross, GA 30093 cliolab.com

have had the o	opportunity to ask questions I might have about the testing, the procedure, the risks, and the alternatives prior to my ent. I agree to have the molecular genetic testing described within or above.
	have had read to me all of the above statements and understand the information regarding molecular genetics testing ar
meth	ort additional testing results (other than requested) if they are clinically relevant to the patients and their families (e.g. The nodologies for evaluating specific gene(s) of interest may rarely identify incidental findings related or unrelated to the ion I/my child have been offered testing. Insuch instances
Refu	use testing if one of the conditions in this informed consent document is not met.
Sugg	gest additional molecular testing if it would help in resolving your clinical genotyping.
I unders	stand thalaboratory reserves the right to:
○ I	In addition to agreeing above, I agree to be contacted regarding research opportunities.
○ 1	I am a New York state resident and I give permission to store my sample for up to I year after testing completion.
	I agree to use of my de-identified bio specimen for research to improve genetic testing for all patients and contribute to scientific research.
	lab is committed to improving genetic testing for all patients and contributing to scientific research. NOTE: If left blank, sent is interpreted as "NO".
I unders	stand the following information regarding use of specimens for research:
unav	derstand that inaccurate results may occur as a result of (but not limited to) the following reasons: sample mixup, sample vailable from critical family members, inaccurate reporting of family relationships, inaccurate or misleading medical remation about my clinical condition or that of my family members, or technical problems.
I unders	stand the following information regarding standard laboratory limitations:
muta	le this test is designed to identify most detectable mutations in the genes analyzed, it is still possible that there are ations that this testing technology is unable to detect. In addition, there may be other genes associated with cancer ceptibility that are not included on this panel or that are not known at this time.
I unders	stand the following information regarding technical limitations of this testing:
(for e feder inforr "Prot (Publ	re are federal laws inplace: that prohibit health insurers and employers from discriminating based on genetic information example, the Genetic Information Nondiscrimination Act (GINA) of 2008 (Public Law J 10-233). There are currently no eral laws that prohibit life insurance, long-term care, or disability insurance companies from discriminating based on generation. Your state may have more comprehensive laws in this area. The results of genetic resting are considered tected Health Information" (PHI) as described in the Health Insurance Portability and Accountability Act (HIPAA) of 1996 blic Law 104-191). Release of test results is limited to authorized personnel, such as the ordering physician, and to other less as required by law.